Abstract
The adoptive transfer of T cells specific for antigens encoded by pathogens and tumors has been an effective treatment for infections and malignancies in animal models and is potentially applicable for infections occurring in immunodeficient bone marrow transplant recipients. This article reviews recent insights derived from studies of the immunobiology of human cytomegalovirus (CMV) infection in healthy and immunodeficient hosts and the development of adoptive immunotherapy as prophylaxis for CMV infection in recipients of allogeneic bone marrow transplants.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Animals
-
Antigens, Viral / immunology
-
Bone Marrow Transplantation* / adverse effects
-
Cells, Cultured / transplantation
-
Cytomegalovirus / immunology
-
Cytomegalovirus Infections / etiology
-
Cytomegalovirus Infections / immunology
-
Cytomegalovirus Infections / prevention & control*
-
Cytomegalovirus Infections / therapy
-
Cytomegalovirus Infections / transmission
-
Humans
-
Immediate-Early Proteins / immunology
-
Immunocompetence
-
Immunocompromised Host
-
Immunodominant Epitopes / immunology
-
Immunotherapy, Adoptive*
-
Lymphopenia / complications
-
Lymphopenia / therapy
-
Mice
-
Mice, Inbred BALB C
-
T-Lymphocytes, Cytotoxic / immunology
-
T-Lymphocytes, Cytotoxic / transplantation*
-
Viral Structural Proteins / immunology
Substances
-
Antigens, Viral
-
Immediate-Early Proteins
-
Immunodominant Epitopes
-
Viral Structural Proteins